Covid-19 related revenue equated to 14.4% of our total revenue. Currency movements in U.S. Dollars and Brazilian Real had a negative impact in 2021.
Excluding this effect, the increase in revenue on a constant currency basis was 36.3%.
Biopharmaceutical and Diagnostic Solutions segment
Revenue generated by the Biopharmaceutical and Diagnostic Solutions segment increased by 32.4 million, or 22.7%, to 174.8 million for the
three months ended June 30, 2021, compared to 142.4 million in the three months ended June 30, 2020. For the three months ended June 30, 2021, high-value solutions accounted for approximately 27.5% of revenue, compared to
26.5% for the three months ended June 30, 2020. Revenue growth for this segment was due in part to a general increase in our high-value solutions sales by 10.4 million, or 27.4%, to 48.1 million for the three months ended
June 30, 2021, compared to 37.7 million for the three months ended June 30, 2020, driven by increased demand. In addition, other containment and delivery solutions sales grew by 22.0 million, or 21.0%, to
126.7 million for the three months ended June 30, 2021, compared to 104.7 million for the three months ended June 30, 2020.
On a constant currency basis, revenue generated by high-value solutions increased by 12.4 million, or 32.9%, for the three months ended
June 30, 2021, while revenue generated by other containment and delivery solutions increased by 24.0 million, or 22.9%.
Revenue generated
by the Biopharmaceutical and Diagnostic Solutions Segment increased by 72.6 million, or 27.6%, to 335.4 million for the six months ended June 30, 2021, from 262.8 million for the six months ended June 30,
2020. Revenue growth for this segment was due to in part: (i) the increase in sales volumes of our premium priced high-value solutions, which grew by 25.1 million, or 36.9%, to 93.0 million for the six months
ended June 30, 2021, compared to 68.0 million for the six months ended June 30, 2020 driven by increased demand, and reflecting our continuing efforts to strategically shift towards a product mix that includes a higher
proportion of high-value solutions, such as EZ-Fill® products and molecular diagnostic plastic parts; and (ii) a general increase in
demand for our other containment and delivery solutions due to the increasing impact of Covid-19 on our industry and delivery of previously placed orders, which caused sales to increase by
47.5 million, or 24.4%, to 242.4 million for the six months ended June 30, 2021, from 194.9 million for the six months ended June 30, 2020. Covid-19 contributed to a
higher demand for our products, causing a revenue increase which more than offset any decrease in sales of our products to businesses impacted by Covid-19 such as anesthetic, diagnostic, plastic and minor
surgeries related businesses.
On a constant currency basis, revenue generated by high-value solutions increased by 29.2 million, or 43.0%, for
the six months ended June 30, 2021, while revenue generated by other containment and delivery solutions increased by 53.2 million, or 27.3%.
The Company monitors its utilization rates in its Biopharmaceutical and Diagnostics Solutions Segment (BDS) in order to appropriately plan for its longer-term
capacity needs. The Company works in partnership with its clients to determine their required product needs, production timing and order delivery. While utilization rates vary from product to product, the Company currently estimates that it has an
average utilization rate in its BDS Segment of approximately 80% to 85%.
Engineering segment
Revenue generated by the Engineering segment increased by 9.7 million, or 50.0%, to 29.1 million for the three months ended June 30,
2021, compared to 19.4 million for the three months ended June 30, 2020. Revenue increase in this segment and in all our product lines, namely glass converting machines, visual inspection systems and assembly and packaging machines.
Revenue generated by the Engineering Segment, increased by 26.0 million, or 73.4%, to 61.4 for the six months ended June 30, 2021,
compared to 35.4 million for the six months ended June 30, 2020. Growth in this segment was mainly driven by higher sales of visual inspection systems as well as glass forming machines for a total of 22.3 million.
Revenue further grew by 3.0 million as a result of our attempts to better serve our customers and to increase our share in after sales area, as well as by 0.7 million increase in packaging and assembly business.
We do not consider any of the revenue in our Engineering segment to be attributable to Covid-19 on the basis that we
cannot accurately determine the end uses of our products and that most of our products have life cycles of 10 years or more, and therefore bear a reasonably likely chance of being used for purposes other than
Covid-19 related.
Revenue Breakdown by Region
Our ongoing geographic expansion resulted in an increase in sales in all geographic regions where we operate. For the three months ended June 30, 2021, in
APAC we experienced the fastest growth. For the three months ended June 30,
41